Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
A technology of tafluprost and composition, applied in the field of drug therapy, can solve the problems of limited volume and capacity of lacrimal sac, adverse drug effect and the like
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach
[0098] CLAIMS 1. A pharmaceutical composition comprising tafluprost and a semifluorinated alkane for use in a method of treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or symptoms associated therewith.
[0099] 2. The pharmaceutical composition for said use according to clause 1, wherein said semifluorinated alkane is selected from 1-perfluorohexyloctane or 1-perfluorobutylpentane, preferably 1-perfluorohexyl octane.
[0100] 3. The pharmaceutical composition for said use according to any one of the preceding clauses, wherein said tafluprost target dose per eye is in the range of about 0.20 μg to 0.55 μg, preferably about In the range of 0.30 μg to 0.50 μg, more preferably in the range of 0.30 μg to 0.45 μg.
[0101] 4. The pharmaceutical composition for said use according to any one of the preceding clauses, wherein the concentration of said tafluprost is in the range of about 0.002% w / v to 0.005% w / v.
[0102] 5. The pharmaceutical compositio...
Embodiment 1
[0145] The study described below was carried out to evaluate the pharmacodynamics of tafluprost in normotensive dogs following repeated administration of topical ocular doses of tafluprost in 1-perfluorohexyloctane (F6H8) ( intraocular pressure (IOP), and evaluate the pharmacokinetics of tafluprost in aqueous humor. The dog is a suitable species for evaluating the ocular distribution and pharmacodynamics of prostaglandin analogs; this model can also provide quantitative pharmacokinetic data.
[0146] Study settings:
[0147] Animals for the study were selected based on general health, body weight, ophthalmic examination results, response to IOP stimulation, and the following criteria:
[0148] - Healthy, normal ocular surface;
[0149] - Have not had invasive eye surgery for at least one month prior to the study; in particular no surgery involving the cornea or anterior segment;
[0150] - No topical or systemic corticosteroid therapy for at least one month;
[0151] - T...
PUM
Property | Measurement | Unit |
---|---|---|
density | aaaaa | aaaaa |
surface tension | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com